View : 503 Download: 0
Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: Possible involvement of ERK and p38 MAPK pathways
- Title
- Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: Possible involvement of ERK and p38 MAPK pathways
- Authors
- Takami M.; Cho E.S.; Lee S.Y.; Kamijo R.; Yim M.
- Ewha Authors
- 이수영
- SCOPUS Author ID
- 이수영
- Issue Date
- 2005
- Journal Title
- FEBS Letters
- ISSN
- 0014-5793
- Citation
- FEBS Letters vol. 579, no. 3, pp. 832 - 838
- Indexed
- SCI; SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Phosphodiesterases (PDEs) are enzymes that degrade intracellular cAMP. In the present study, 3-isobutyl-1-methylxanthine (IBMX) and pentoxifylline, PDE inhibitors, induced osteoclast formation in cocultures of mouse bone marrow cells and calvarial osteoblasts. These inhibitors induced the expression of the osteoclast differentiation factor, TNF-related activation induced cytokine (TRANCE, identical to RANKL, ODF, and OPGL), in calvarial osteoblasts. IBMX induced phosphorylation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) in osteoblasts. Induction of TRANCE expression by IBMX was partially suppressed by the inhibitors of protein kinase A (PKA), ERK, and p38 MAPK, suggesting that activation of ERK and p38 MAPK, as well as PKA, is involved in TRANCE expression by IBMX. Osteoblasts expressed PDE4, a PDE subtype, and rolipram, a selective inhibitor of PDE4, induced TRANCE expression. These results suggest that PDE4 is a key regulator of TRANCE expression in osteoblasts, which in turn controls osteoclast formation. © 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
- DOI
- 10.1016/j.febslet.2004.12.066
- Appears in Collections:
- 자연과학대학 > 생명과학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML